Potentially curative gene therapies are among a number of exciting new sickle cell disease (SCD) drugs set to hit the US market, according to data and analytics company GlobalData.
One of the gene therapies that is currently closest to entering the market - bluebird bio's (Nasdaq: BLUE) bb1111(lovotibeglogene autotemcel) - is projected to represent over a quarter of total sales within the space by 2030, though the US Food and Drug Administration (FDA) has placed the clinical program for the drug on partial clinical hold for patients under the age of 18.
Meanwhile, Droxia (hydroxycarbamide), a treatment from Bristol Myers Squibb (NYSE: BMY) that once was the only approved drug for 20 years, will be drowned out by the newcomers, GlobalData predicts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze